<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03115632</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00077482</org_study_id>
    <nct_id>NCT03115632</nct_id>
  </id_info>
  <brief_title>Contributing Factors in the Pathobiology of Airway Remodeling in Obesity</brief_title>
  <official_title>Contributing Factors in the Pathobiology of Airway Remodeling in Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There are two aims for this study. The purpose of this study is to determine the effects of&#xD;
      body weight and hormones on airway fibrosis (scarring) and lung function in obese &amp; lean&#xD;
      asthma subjects compared to obese &amp; lean non-asthma subjects (Aim 1). And in obese subjects&#xD;
      with asthma undergoing bariatric surgery compared to obese non-asthma subjects undergoing&#xD;
      bariatric surgery (Aim 2).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Main Study&#xD;
&#xD;
      Specific Aim 1: Determine the effects of signaling on airway fibrosis and lung function in&#xD;
      obese asthma and non-asthma patients. The investigators will:&#xD;
&#xD;
      •Perform assessments to determine if obese, early-onset asthma patients are more susceptible&#xD;
      to airway fibrosis and remodeling than lean, early-onset asthma patients and obese and lean,&#xD;
      non-asthma patients.◦&#xD;
&#xD;
      Specific Aim 2: Investigate the mechanism by which bariatric surgery slows the progression of&#xD;
      airway fibrosis in obese human asthma. The investigators will:&#xD;
&#xD;
      •Perform assessments to determine if airway fibrosis in obese, early-onset asthma and obese&#xD;
      non-asthma patients improves following bariatric surgery and weight loss◦&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 9, 2018</start_date>
  <completion_date type="Anticipated">April 13, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 13, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Airway fibrosis</measure>
    <time_frame>Visit 2 (14 days)</time_frame>
    <description>Obese asthmatics compared to lean asthmatics, obese non-asthmatics and lean non-asthmatics: A univariate linear model will be constructed to measure the effect of leptin or GLP-1 (glucagon-like peptide-1) on airway fibrosis, as measured by the ratio of Masson's trichrome-stained area to non-stained area in the sub-mucosal region of airway biopsy tissue.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in airway fibrosis</measure>
    <time_frame>Visit 2 (14 days), Visit 4 (1 year + 14 days)</time_frame>
    <description>Asthmatics undergoing bariatric surgery and non-asthmatics undergoing bariatric surgery: Each patient will serve as its own control in comparing pre- and post-operative airway fibrosis. A univariate linear model will be constructed to measure the effect of bariatric surgery on airway fibrosis, as measured by the ratio of Masson's trichrome-stained area to non-stained area in the sub-mucosal region of airway biopsy tissue.</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Asthma</condition>
  <condition>Obesity</condition>
  <condition>Obesity, Morbid</condition>
  <condition>Bariatric Surgery Candidate</condition>
  <arm_group>
    <arm_group_label>Obese asthmatic &amp; lean asthmatic</arm_group_label>
    <description>men and women with asthma and either obese or lean BMI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese non-asthmatic &amp; lean non-asthmatic</arm_group_label>
    <description>men and women without asthma and either obese or lean BMI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Asthmatic undergoing bariatric surgery</arm_group_label>
    <description>Obese asthmatic men and women undergoing bariatric surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-asthmatic undergoing bariatric surgery</arm_group_label>
    <description>Obese men and women undergoing bariatric surgery</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood plasma, bronchoscopy with endobronchial biopsy and brushings, bronchoalveolar lavage,&#xD;
      RNA&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects will be recruited from the clinics of the Duke Asthma, Allergy and Airway Center,&#xD;
        the Duke Metabolic and Weight Loss Surgery Center, the Duke Raleigh Weight Loss Surgery&#xD;
        Center, and the Duke Diet and Fitness Center. Healthy controls without lung disease will be&#xD;
        recruited from the surrounding area.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Obese asthmatic &amp; lean asthmatic&#xD;
&#xD;
          1. Outpatient adults of either sex 18-60 years of age with an initial asthma diagnosis at&#xD;
             &lt; 12 years of age, as defined by the NHLBI National Asthma Education and Prevention&#xD;
             Program (NAEPP) guidelines.&#xD;
&#xD;
          2. Lean subjects with body mass index (BMI) ≥ 20 kg/m2 and &lt; 30 kg/m2 or obese subjects&#xD;
             with BMI ≥ 30 and ≤ 55 kg/m2&#xD;
&#xD;
          3. Physician diagnosis of asthma&#xD;
&#xD;
          4. Forced expiratory volume at one second (FEV1) within acceptable limits (&gt;45% predicted&#xD;
             before and &gt;55% predicted after, bronchodilator administration).&#xD;
&#xD;
          5. Negative pregnancy test in women of childbearing potential (confirmed during&#xD;
             screening).&#xD;
&#xD;
          6. Relatively healthy subjects able to undergo bronchoscopy without complications.&#xD;
&#xD;
          7. Willing and able to give informed consent and adhere to visit/protocol schedules.&#xD;
&#xD;
          8. Read and write in English.&#xD;
&#xD;
        Obese non-asthmatic &amp; Lean non-asthmatic&#xD;
&#xD;
          1. Outpatient adults of either sex 18-60 years of age.&#xD;
&#xD;
          2. Lean subjects with body mass index (BMI) ≥ 20 kg/m2 and &lt; 30 kg/m2 or obese subjects&#xD;
             with BMI ≥ 30 and ≤ 55 kg/m2&#xD;
&#xD;
          3. Negative pregnancy test in women of childbearing potential (confirmed during&#xD;
             screening).&#xD;
&#xD;
          4. Normal lung function.&#xD;
&#xD;
          5. No clinical history of atopy.&#xD;
&#xD;
          6. No significant medical or psychological issues.&#xD;
&#xD;
          7. Healthy subjects able to undergo bronchoscopy without complications.&#xD;
&#xD;
          8. Willing and able to give informed consent and adhere to visit/protocol schedules.&#xD;
&#xD;
          9. Read and write in English.&#xD;
&#xD;
        Asthmatic undergoing bariatric surgery&#xD;
&#xD;
          1. Outpatient adults of either sex 18-60 years of age with an initial asthma diagnosis at&#xD;
             &lt; 12 years of age, as defined by the NHLBI NAEPP guidelines.&#xD;
&#xD;
          2. Physician diagnosis of asthma&#xD;
&#xD;
          3. FEV1 within acceptable limits (&gt;45% predicted before and &gt;55% predicted after,&#xD;
             bronchodilator administration).&#xD;
&#xD;
          4. Morbidly obese subjects undergoing bariatric surgery and receiving care at the Duke&#xD;
             Metabolic and Weight Loss Surgery Center.&#xD;
&#xD;
          5. Negative pregnancy test in women of childbearing potential (confirmed during&#xD;
             screening).&#xD;
&#xD;
          6. Relatively healthy subjects able to undergo bronchoscopy without complications.&#xD;
&#xD;
          7. Willing and able to give informed consent and adhere to visit/protocol schedules.&#xD;
&#xD;
          8. Read and write in English.&#xD;
&#xD;
        Non-Asthmatic undergoing bariatric surgery&#xD;
&#xD;
          1. Outpatient adults of either sex 18-60 years of age.&#xD;
&#xD;
          2. Morbidly obese subjects undergoing bariatric surgery and receiving care at the Duke&#xD;
             Metabolic and Weight Loss Surgery Center.&#xD;
&#xD;
          3. Negative pregnancy test in women of childbearing potential (confirmed during&#xD;
             screening).&#xD;
&#xD;
          4. Normal lung function.&#xD;
&#xD;
          5. No clinical history of atopy.&#xD;
&#xD;
          6. No significant medical or psychological issues.&#xD;
&#xD;
          7. Healthy subjects able to undergo bronchoscopy without complications.&#xD;
&#xD;
          8. Willing and able to give informed consent and adhere to visit/protocol schedules.&#xD;
&#xD;
          9. Read and write in English.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Children &lt; 18 years of age.&#xD;
&#xD;
          2. Adults ≥ 18 years of age with an initial asthma diagnosis at ≥ 12 years of age, as&#xD;
             defined by the NHLBI NAEPP guidelines.&#xD;
&#xD;
          3. Inpatient status.&#xD;
&#xD;
          4. FEV1 is less than 45% predicted before, or less than 55% predicted after,&#xD;
             bronchodilator administration.&#xD;
&#xD;
          5. Upper or lower respiratory tract infection within one month of the study.&#xD;
&#xD;
          6. Use of inhaled or systemic corticosteroids within four weeks of study.&#xD;
&#xD;
          7. Use of long-acting beta-2, GLP-1 receptor agonists, or dipeptidyl peptidase-4 (DPP-4)&#xD;
             inhibitors within two weeks of study.&#xD;
&#xD;
          8. Smoking history &gt; 5 pack years or any cigarette use within the previous six months.&#xD;
&#xD;
          9. Significant non-asthma pulmonary disease (stable obstructive sleep apnea is not&#xD;
             excluded).&#xD;
&#xD;
         10. Positive pregnancy test for women and/or nursing women.&#xD;
&#xD;
         11. An emergency department visit or inpatient admission for a primary respiratory&#xD;
             diagnosis or treatment with antibiotics within 60 days of enrollment.&#xD;
&#xD;
         12. Poorly controlled concomitant conditions that pose additional procedure risk as&#xD;
             determined by the investigator.&#xD;
&#xD;
         13. All patients on anticoagulants&#xD;
&#xD;
         14. Uncontrolled sleep apnea&#xD;
&#xD;
         15. Use of e-cigarettes or &quot;vape&quot; devices of any kind&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Loretta Que, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antoinette Santoro</last_name>
    <phone>919-479-0861</phone>
    <email>maria.santoro@duke.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Catherine Foss</last_name>
    <phone>919-479-0861</phone>
    <email>catherine.foss@duke.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Duke Metabolic and Weight Loss Surgery Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Duke Asthma Allergy and Airway Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Loretta Que</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>April 4, 2017</study_first_submitted>
  <study_first_submitted_qc>April 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2017</study_first_posted>
  <last_update_submitted>July 23, 2021</last_update_submitted>
  <last_update_submitted_qc>July 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Obesity, Morbid</mesh_term>
    <mesh_term>Airway Remodeling</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

